Acid Suppression Therapy: Where Do We Go from Here?

Cites (284)

Items 201–279 of 279

1. Effects of IY-81149, a Newly Developed Proton Pump Inhibitor, on Gastric Acid Secretion in vitro and in vivo
   Dow Kwon, Joo Chae, Chan Hyuk Park, Yong H. Kim, Seung Hwan Lee, Eun Sun Kim, In Huh, Dong Kim, K. H. Cho · 2011 · Arzneimittelforschung
2. Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use?
   Masahiko Inamori, Jun-Ichi Togawa, Tomoyuki Iwasaki, Yutaka Ozawa, Taisuke Kikuchi, Kenichi Muramatsu, Gaku Chiguchi, Shuhei Matsumoto, Harunobu Kawamura, Yasunobu Abe et al. · 2005 · Journal of Gastroenterology
3. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O)
   Tommy Andersson, Eva Bredberg, Maria Sunzel, Madeleine Antonsson, Lars O. G. Weidolf · 2000 · Gastroenterology
4. Lafutidine Changes Levels of Somatostatin, Calcitonin Gene-Related Peptide, and Secretin in Human Plasma
   Hiroki Itoh, Takafumi Naito, Masaharu Takeyama · 2002 · Biological and Pharmaceutical Bulletin
5. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazolein vitro
   K. H. Liu, M. J. Kim, J SHON, Y. S. Moon, Sang Yong Seol, Wonku Kang, I. J. Cha, Jae‐Gook Shin · 2005 · Xenobiotica
6. General Pharmacology of IY-81149, a New Proton Pump Inhibitor
   Eun Sil Kim, Rae Lee, Seung‐Hwan Lee, Dong Kim · 2011 · Arzneimittelforschung
7. Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative
   Laura Revel, Flora Ferrari, Francesco Makovec, Lucio Claudio Rovati, Mariannina Impicciatore · 1992 · European Journal of Pharmacology
8. Synergy between low‐dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal‐induced heartburn
   MALCOLM G. ROBINSON, Sheila Rodriguez-Stanley, Arthur A. Ciociola, Jonathan Filinto, Sattar M. Zubaidi, Philip B. Miner, Jerry D. Gardner · 2001 · Alimentary Pharmacology & Therapeutics
9. L-365,260, a Potent CCK-B/Gastrin Receptor Antagonist, Suppresses Gastric Acid Secretion Induced by Histamine and Bethanechol as Well as Pentagastrin in Rats.
   Akito Nishida, Hidenobu Yuki, Rie Tsutsumi, Keiji Miyata, Takeshi Kamato, H Ito, Mayumi Yamano, Kazuo Honda · 1992 · The Japanese Journal of Pharmacology
10. Edkins and a Century of Acid Suppression
    Irvin Mark Modlin, George M. Sachs, N. Wright, Mark S. Kidd · 2005 · Digestion
11. Rapid progression to liver cirrhosis of toxic hepatitis due to ebrotidine
    Juan Antonio Pineda, Juan Larraui, Juan Macı́as, Angel Hernández, Javier Guijarro, Manuel Sayago, Francisco Gavilán, José Aguilar, Eduardo Lissen · 1999 · Journal of Hepatology
12. Role of gastrin and cholecystokinin receptors in regulation of peptone-stimulated gastric cid secretion in conscious rats
    Gábor Varga, Donald R. Campbell, Louis J. Bussjaeger, Travis E. Solomon · 1993 · European Journal of Pharmacology
13. Neural control of the release and action of secretin.
    WOO YOON CHEY, TM Chang · 2003 · PubMed
14. Inhibition of gastrin‐ and histamine‐stimulated gastric acid secretion by gastrin and cholecystokinin antagonists in the rat
    Barry Hugo Hirst, K. J. ELLIOTT, Hamish Ryder, Michael Szelke · 1991 · Alimentary Pharmacology & Therapeutics
15. Comparison of IY81149 with omeprazole in rat reflux oesophagitis
    B. J. Kil, I. W. Kim, C. Y. Shin, J. H. Jeong, C. H. Jun, S. M. Lee, Dong Young Kim, In Hoi Huh, Uy Dong Sohn · 2000 · Journal of Autonomic Pharmacology
16. The Cellular Localization of the Cholecystokinin 2 (Gastrin) Receptor in the Stomach
    Helge Lyder Waldum, Per Martin Kleveland, Arne K. Sandvik, Eiliv Brenna, Unni Syversen, Ingunn Bakke, Karin A. Tømmerås · 2002 · Pharmacology & Toxicology
17. Are there unmet needs in acid suppression?
    G. N. J. Tytgat · 2004 · Best Practice & Research Clinical Gastroenterology
18. Stereoselective Metabolism by Human Liver CYP Enzymes of A Substituted Benzimidazole
    Angela Äbelö, Tommy B. Andersson, Ulf Bredberg, Inger Skånberg, Lars O. G. Weidolf · 2000 · Drug Metabolism and Disposition
19. Separation and identification of cis and trans isomers of 2-butene-l,4-diol and lafutidine by HPLC and LC-MS
    Chunxiu Pan, Xiuzhu Xu, Hong-mei He, Xiaojun Cai, Xue-jun Zhang · 2004 · Journal of Zhejiang University SCIENCE B
20. Combination Drug Therapy for Gastroesophageal Reflux Disease
    L. Brian Cross, Lori N Justice · 2002 · Annals of Pharmacotherapy
21. Are there indications for intravenous acid-inhibition in the prevention and treatment of upper GI bleeding?
    William P. Geus · 2000 · PubMed
22. A Novel Histamine 2(H2) Receptor Antagonist with Gastroprotective Activity. II. Synthesis and Pharmacological Evaluation of 2-Furfuryl-thio and 2-Furfurylsulfinyl Acetamide Derivatives with Heteroaromatic Rings.
    Nobuhiko HIRAKAWA, Hajime MATSUMOTO, Akihiko Hosoda, Akihiro SEKINE, Tetsuaki Yamaura, Yasuo SEKINE · 1998 · Chemical and Pharmaceutical Bulletin
23. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes
    Masatomo Miura, Hitoshi Tada, Norio Yasui‐Furukori, Tsukasa Uno, Kazunobu Sugawara, Tomonori Tateishi, Toshio Suzuki · 2005 · Chirality
24. Comparative effects of an omeprazole antacid complex-immediate release (OAC-IR) and omeprazole-delayed release (OME-DR) on omeprazole pharmacokinetics (PK) and gastric pH in healthy subjects
    Bonnie Hepburn, Barry Goldlust · 2003 · Gastroenterology
25. Omeprazole in the Treatment of Zollinger-Ellison Syndrome and Histamine H 2 -Antagonist Refractory Ulcers
    J.L. Meijer, Jan B.�M.�J. Jansen, C. B. H. W. Lamers · 2009 · Digestion
26. Clinical Study on the Pathophysiology and Treatment of PPI-Resistant Ulcers
    Kiyoshi Ashida, Masahiro Sakaguchi, Masaya Tanaka, Hiroya Takiuchi, Yutaro Egashira, Ken‐ichi Katsu · 1995 · Journal of Clinical Gastroenterology
27. Antisecretory Drugs for Eradication of Helicobacter pylori: Antibacterial Activity and Synergism with Antimicrobial Agents
    Carmelo Scarpignato, Iva Pelosini · 1999 · KARGER eBooks
28. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis
    Anan S. Raghunath, Jonathan R.B. Green, Steven J Edwards · 2003 · Clinical Therapeutics
29. Novel therapeutic strategies in acid-related disorders
    Marcello Tonini, Roberto DE GIORGIO, Fabrizio De Ponti · 2003 · Expert Opinion on Therapeutic Patents
30. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube
    James W. Freston, Michael J. Kukulka, E. Lloyd, C. Lee · 2004 · Alimentary Pharmacology & Therapeutics
31. Lansoprazole Oro-Dispersible Tablet
    Fabio Baldi · 2005 · Drugs
32. Unique Profile of Lafutidine, A Novel Histamine H2-Receptor Antagonist - Mucosal Protection Throughout Gastrointestinal Tract Mediated by Capsaicin-Sensitive Afferent Neurons -
    Sadayoshi Onodera, K Nishida, Koji Takeuchi · 2004 · Drug Design Reviews - Online
33. Enzymes in stereoselective pharmacokinetics of endogenous substances
    A Marzo, Gloria Cardace, E. Arrigoni Martelli · 1992 · Chirality
34. Histamine receptor antagonists, proton pump inhibitors and their combination in the treatment of gastro-oesophageal reflux disease
    Philip O. Katz, Radu I. Tutuian · 2001 · Best Practice & Research Clinical Gastroenterology
35. Pharmacokinetics of Tenatoprazole, a Newly Synthesized Proton Pump Inhibitor, in Healthy Male Caucasian Volunteers
    Florence Domagala, Hervé Ficheux, Georges Houin, Jérôme Barré · 2011 · Arzneimittelforschung
36. Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula.
    Y Takemoto, Hidenobu Yuki, Akito Nishida, H Ito, A. Kobayashi-Uchida, Yusuke Takinami, Shinobu Akuzawa, Mitsuaki Ohta, M Satoh, Graeme Semple et al. · 1998 · PubMed
37. Enantiomers: Implications and Complications in Developmental Pharmacology
    Michel F Eichelbaum · 2019 · Developmental Pharmacology and Therapeutics
38. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
    Bronislaw L. Slomiany, J Piotrowski, A. Slomiany · 1997 · PubMed
39. Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: Still an unexplored triangle
    Carmelo Scarpignato · 2005 · Digestive and Liver Disease
40. Potent and Long-Lasting Action of Lafutidine on the Human Histamine H2 Receptor
    Yasushi Fukushima, Hiroko Otsuka, Minako Ishikawa, Tomoichiro Asano, Motonobu Anai, Takao Katsube, Kenji Ogawa, Tetsuro Kajiwara, Shin-ichiro Ohkawa, Takashi Ishikawa et al. · 2001 · Digestion
41. New Perspectives in Gastric Acid Suppression: Genetic Polymorphisms Predict the Efficacy of Proton Pump Inhibitors
    Laurence John Egan, Joseph A. Murray · 2000 · Digestive Diseases
42. drug development in gastroenterology—the changing view of industry
    Michael E. Parsons, A. Garner · 1995 · Alimentary Pharmacology & Therapeutics
43. Gastrimmune‐induced antigastrin‐17 antibodies inhibit acid secretion in a rat fistula model
    Andrew Malvern Smith, T. Morris, Tim A. Justin, D Michaeli, S. A. Watson · 2001 · Alimentary Pharmacology & Therapeutics
44. Effects of TU-199, a novel H+, K+-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats
    Kazuyuki Uchiyama, Wakatsuki, D., Bunpei Kakinoki, Yu Takeuchi, Takaaki Araki, Yasuhiro Morinaka · 1999 · Methods and Findings in Experimental and Clinical Pharmacology
45. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
    P C Konturek, T Brzozowski, Konturek Si, M Márquez, J Torres, J A Ortiz · 1997 · PubMed
46. Correct and incorrect dosing of proton pump inhibitors and its impact on GERD symptoms
    Jonathan P. Pezanoski, Naresh T. Ganuratnam, Mark E. Cowen · 2003 · Gastroenterology
47. Cholecystokinin Antagonists and Motilides: Pharmacology and Potential in the Treatment of Gastroesophageal Reflux Disease and Other Digestive Motor Disorders
    Carmelo Scarpignato · 2015 · Frontiers of gastrointestinal research
48. The cytoprotective effect of leminoprazole on indomethacin-induced damage to rabbit gastric mucosal cells.
    Satoru Takahashi, Shigeo Okabe · 1996 · Journal of Pharmacology and Experimental Therapeutics
49. Triiodothyronine (T3) does not induce Rankl expression in rat Ros 17/2.8 cells
    Patrícia Pinto Saraiva, Silvania da Silva Teixeira, Célia Regina Nogueira, Carlos Roberto Padovani · 2008 · Arquivos Brasileiros de Endocrinologia & Metabologia
50. Control of gastric acid with high dose H2-receptor antagonists after omeprazole failure: report of two cases.
    Louis P. Leite, Robert Just, Donald O. Castell, P O Lagerström · 1995 · PubMed
51. The action of antacids on serum gastrin concentrations in man
    Gerhard E. Feurle · 1977 · Journal of Molecular Medicine
52. CCK-B Antagonists in the Control of Anxiety and Gastric Acid Secretion
    Mark S. Chambers, Stephen Robert Fletcher · 2000 · Progress in medicinal chemistry
53. Intestinal protection by lafutidine, a histamine H(2)-receptor antagonist, against indomethacin-induced damage in rats--role of endogenous nitric oxide.
    Akiko Tanaka, Hiroyuki Mizoguchi, Satoshi Hase, T Miyazawa, K Takeuchi · 2001 · PubMed
54. Effects of Z-360, a novel CCKB/gastrin (CCK2) receptor antagonist, on meal-induced acid secretion and experimental ulcer models in dogs and rats
    Hitoshi Morita, Naoyoshi Miura, Yuko Hori, Yugo Matsunaga, Hideki Ukawa, Hiroshi Suda, Tomoyuki Yoneta, Tadashi Kurimoto, Zen Itoh · 2001 · Gastroenterology
55. CP-66,948: An antisecretory histamine H2-receptor antagonist with mucosal protective properties
    John P. Hakkinen, William F. Holt, Carl J. Goddard, Peter J. Oates, William R.C. Murphy, James J. Maciejko, Lawrence A. Reiter · 1991 · Digestive Diseases and Sciences
56. Esomeprazole, the S-isomer of omeprazole, is optically stable in humans
    Mohammed Hassan‐Alin, Mohammad Niazi, Kerstin M. Rohss, Per-Olof Lagerström · 2000 · Gastroenterology
57. Pentanoic Acid Derivatives
    Lucio Claudio Rovati · 1991 · Springer eBooks
58. Peptides: Gastrointestinal Hormones
    Giulio Bertaccini · 1982 · Handbook of experimental pharmacology
59. Lafutidine inhibits Helicobacter pylori‐induced interleukin‐8 production in human gastric epithelial cells
    Yoshihisa Nozawa, Katsushi Nishihara, Yushiro Akizawa, Naoki Orimoto, Motoko Nakano, Tatsuya Uji, Hirofusa Ajioka, ATSUHIRO KANDA, Naosuke Matsuura, Mamoru Kiniwa · 2004 · Journal of Gastroenterology and Hepatology
60. Human Pharmacokinetics and Tolerability of L‐365,260, a Novel Cholecystokinin‐B Antagonist
    Kenneth Grasing, M. Gail Murphy, Juinn H. Lin, Mary E. Swigar, Debra Freedholm, Laura Clarke, Ji Zhang, Owen M. Wolkowitz, Herbert Weingartner, Karen T. Putnam et al. · 1996 · The Journal of Clinical Pharmacology
61. Liver injury caused by ebrotidine: a new example of the utility of the postmarketing surveillance
    J. R. Castillo, Jaime Torelló, A. Hernandez · 2000 · European Journal of Clinical Pharmacology
62. Gastrin and gastrin receptor ligands - a review of recent patent literature.
    Katherine I. M. Steel · 2002 · PubMed
63. Improving opportunities for effective management of gastro-oesophageal reflux disease
    Simone Vigneri · 2001 · Digestive and Liver Disease
64. Mechanism by Which Orally Administered Leminoprazole Stimulates Mucus Synthesis in Rats
    Satoru Takahashi, Susumu Okabe · 1998 · Pharmacology
65. Persistent gastroesophageal reflux disease symptoms on standard proton-pump inhibitor therapy
    Stephen J. Sontag · 2002 · Gastroenterology Clinics of North America
66. Phase 1, randomized, parallel, placebo-controlled, safety, tolerance and pharmacokinetic study of multiple dose of IY-81149 in fasting male volunteers
    Ronald Goldwater, F. Boileau, S.M. Lee, Ga-Young Chung, D.Y. Kim, K.D. Cho · 1999 · Clinical Pharmacology & Therapeutics
67. Gastric acid suppression using anti-gastrin-17 antibodies produced by a gastrin immunogen, gastrimmune, in an in vivo pig model
    TA Justin, SA Watson, D Michaeli, J D Hardcastle, R. Steele · 1995 · Gastroenterology
68. The effect of over the counter ranitidine (75 mg) on nighttime heartburn in patients with erosive esophagitis on daily proton pump inhibitor maintenance therapy
    Nalini M. Guda, Richard Mueller, Nimish B. Vakil · 2003 · Gastroenterology
69. Gastroprotective properties of ebrotidine. A review.
    Bronislaw L. Slomiany, J. Piotrowski, A. Slomiany · 1997 · PubMed
70. General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-(((methoxy-3,5-dimethylpyrid-2-yl)methyl)sulfinyl)-1H-imidazo(4,5-b)pyridine
    Bunpei Kakinoki, C. Ono, Yamazaki, N., N Chikamatsu, D Wakatsuki, Kazuyuki Uchiyama, Yasuhiro Morinaka · 1999 · Methods and Findings in Experimental and Clinical Pharmacology
71. The lesson of thalidomide
    Leo Stern · 1973 · Clinical Pharmacology & Therapeutics
72. Action of ebrotidine, ranitidine and cimetidine on the specific binding to histamine H1- and H2-receptors.
    Julián Agut, Juan C. Sanchez, Aurelio Sacristan, J A Ortiz · 1997 · PubMed
73. Effects of Histamine H2‐receptor Antagonists on Human Plasma Levels of Motilin, Gastrin, Secretin and Somatostatin
    Masaharu Takeyama, Hiroki Itoh, Tetsuji Hayashi, Toshiaki Nagano · 1998 · Pharmacy and Pharmacology Communications
74. Ebrotidine versus ranitidine in the treatment of acute duodenal ulcer. A multicentre, randomized, double-blind, controlled clinical trial.
    V Matov, G Metchkov, Zahariy A. Krastev, Konstantin Georgiev Tchernev Jr, Rumyana Mitova, M Márquez, J Torres, E Herrero, O Fíllat, J A Ortiz · 1997 · PubMed
75. Reflux gastro-œsophagien résistant aux inhibiteurs de la pompe à protons
    Jean–Paul Galmiche, Sylvie Sacher‐Huvelin · 2002 · Hépato-Gastro & Oncologie Digestive
76. Selective blockade of cholecystokinin type B receptors with L-365,260 does not impair gallbladder contraction in normal humans.
    Kenneth Grasing, Debra Freedholm, Megan Murphy, Mary E. Swigar, Tadeus Russer, John L. Nosher, J Lin, Virginia Frame, L Clarke, James R. Seibold · 1996 · PubMed
77. Discovery of new CCK2 receptor antagonists. A review of pharmacological studies. Part I: Development of potential therapeutic tools for gastrin-related gastrointestinal diseases
    Laura Revel, Francesco Makovec · 1999 · Methods and Findings in Experimental and Clinical Pharmacology
78. Inhibitory Effect of Leminoprazole on Acid Secretion in Parietal Cells Isolated from Guinea Pig Gastric Mucosa
    Eiichi Saito, Yutaka Matsuo · 1995 · The Japanese Journal of Pharmacology
79. [Endogenous gastrin and insulin secretion in humans: effect of gastric lavage with sodium bicarbonate].
    Giovanni Zimbaro, O Ferraù, L Familiari, F Consolo · 1973 · PubMed